Custom mRNA vaccine takes on Hard-to-Treat cancers

NCT ID NCT07182435

Not yet recruiting Disease control Sponsor: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests a personalized mRNA vaccine called RH125 in 36 people with advanced solid tumors who have no standard treatment options left. The vaccine is custom-made based on each patient's tumor mutations and is given alone or with a PD-1 blocker. The main goals are to check safety, immune response, and whether the vaccine can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized mRNA tumor vaccine (RH125)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard options.
What could go wrong: This is a very early Phase 1 trial with only 36 participants, so it is primarily testing safety. The vaccine may not shrink tumors or work for everyone, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR MALIGNANCIES

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center

Shenzhen, Guangdong, 518100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.